Kartellierte internationale Märkte und innovative Produkte: Die Farbenfabriken Bayer und ihre synthetischen Malariawirkstoffe (1924 bis 1937)

The Bayer AG was cut off from the quinine world trade by the quinine cartel, existing mainly of Great Britain, France and Netherlands, during the Great War. Being unable to purchase ingredients to produce malaria drug Bayer decided to develop synthetic active ingredients to treat malaria patients. T...

Full description

Saved in:
Bibliographic Details
Published in:Zeitschrift für Unternehmensgeschichte 2022-03, Vol.67 (1), p.43-72
Main Authors: Avci, Meral, Henrich-Franke, Christian
Format: Article
Language:English
Subjects:
Antimalarial drugs
Change agents
Cooperation
Cost analysis
Exploitation
Innovations
International cooperation
International markets
Malaria
Organizational change
Prestige
Sales
Transformation
Tropical medicine
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Bayer AG was cut off from the quinine world trade by the quinine cartel, existing mainly of Great Britain, France and Netherlands, during the Great War. Being unable to purchase ingredients to produce malaria drug Bayer decided to develop synthetic active ingredients to treat malaria patients. This was an innovative approach to the malaria problem by Bayer’s research department accompanied with an organizational change. This paper analyzes the international cooperation of the Bayer tropical medicine department in the 1920s and 1930s with regard to the development of test fields and sales markets for the synthetic antimalarial agents. How and why did the tropical medicine research department develop into a significant international player with innovative products? How did the tension between international research cooperation and commercial exploitation change? What role did the particular political circumstances and their change play in the transformation of cooperation and the development of markets? By answering these questions, this paper demonstrates that Bayer quite successfully pursued an innovation-based strategy of market development, which aimed at convincing the international scientific community and generating international prestige. Nevertheless, the Italian demand and the specific interests of Italian malaria research – low cost domestic supply of antimalarial drugs, colonial expansionism, and international influence – were crucial door openers for the breakthrough on the international market.
ISSN:0342-2852
2367-2293
DOI:10.1515/zug-2021-0003